Close Menu

influenza

The antibody profile could potentially be used to improve stratification of patient cohorts in clinical trials or as a point-of-care test to determine whether a patient needs vaccination, Reinhard Hiller, managing director of CPGR, told ProteoMonitor.

Doing so, however, will require the company to secure additional funding, and it is currently evaluating its options, a company official said.

CPGR will be developing multiplex protein array-based antibody profiling assays and related bioinformatic analysis methods for the project with the ultimate aim of creating a biomarker signature that can be used for companion diagnostic purposes.

Through their phylogenetic analysis of influenza A strains circulating in pigs at a Hong Kong slaughterhouse, researchers have detected viral reassortment involving the H1N1 "swine flu" virus.

The partners aim to identify biomarkers that may predict how patients react to seasonal influenza vaccinations.

"The discovery of svRNAs that play a critical role in flu virus replication opens the door for the development of novel RNA therapeutics for the treatment of flu infection, an area of major unmet need," according to an Alnylam official.

Simplexa, manufactured by Quest's Focus Diagnostics business, is the first test to be cleared by the FDA to aid in detecting and differentiating influenza A and 2008 H1N1 influenza viral RNA.

As a result of the 510(k) clearance, Quest's Simplexa Influenza A H1N1 test will be the only one that can be marketed after June 23 when the public emergency stemming from the virus is lifted.

The vote of confidence is a stepping stone for the company to seek 510(k) approval for an H1N1 test on its platform; to tackle the point-of-care diagnostic market; and to further develop tests for other infectious diseases.

IQuum said that it has developed a nucleic acid-based test that can provide results in just 26 minutes.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.